Linking Gba1 E326K mutation to microglia activation and mild age-dependent dopaminergic Neurodegeneration.
Linking Gba1 E326K mutation to microglia activation and mild age-dependent dopaminergic Neurodegeneration.
复制标题
将 Gba1 E326K 突变与小胶质细胞激活和轻度年龄依赖性多巴胺能神经变性联系起来。
DOI:
10.1101/2023.09.14.557673
复制
发表时间:
2023
期刊:
影响因子:
--
通讯作者:
Ko,HanSeok
中科院分区:
文献类型:
--
作者:
Kweon,SinHo;Ryu,HyeGuk;Park,Hyeonwoo;Lee,Saebom;Kim,Namshik;Kwon,Seung-Hwan;Ma,Shi-Xun;Kim,Sangjune;Ko,HanSeok
Mutations in the GBA1 gene have been identified as a prevalent genetic risk factor for Parkinson’s disease (PD). GBA1 mutations impair enzymatic activity, leading to lysosomal dysfunction and elevated levels of α-synuclein (α-syn). While most research has primarily focused on GBA1’s role in promoting synucleinopathy, emerging evidence suggests that neuroinflammation may be a key pathogenic alteration caused by GBA1 deficiency. To examine the molecular mechanism underlying GBA1 deficiency-mediated neuroinflammation, we generated Gba1 E326K knock-in (KI) mice using the CRISPR/Cas9 technology, which is linked to an increased risk of PD and dementia with Lewy bodies (DLB). In the ventral midbrain and hippocampus of 24-month-old Gba1 E326K KI mice, we found a moderate decline in GBA1 enzymatic activity, a buildup of glucosylceramide, and an increase in microglia density. Furthermore, we observed increased levels of pro-inflammatory cytokines and formation of reactive astrocytes in primary microglia and astrocytes, respectively, cultured from Gba1 E326K KI mice following treatment with pathologic α-syn preformed fibrils (PFF). Additionally, the gut inoculation of α-syn PFF in Gba1 E326K KI mice significantly enhanced the accumulation of Lewy bodies in the dentate gyrus of the hippocampus, accompanied by aggravated neuroinflammation and exacerbated non-motor symptoms. This research significantly enhances our understanding of the Gba1 E326K mutation’s involvement in neuroinflammation and the cell-to-cell transmission of pathogenic α-syn in the brain, thereby opening new therapeutic avenues.